期刊文献+

血栓导管抽吸联合替罗非班介入治疗STEMI的临床疗效 被引量:3

下载PDF
导出
摘要 目的探讨冠状动脉内导管血栓抽吸术联合盐酸替罗非班介入治疗急性sT段抬高型心肌梗死的临床。方法将本院2012年月-2013年1月收治的急性sT段抬高型心梗患者,随机分成两组,治疗组予行冠状动脉内导管血栓抽吸术联合盐酸替罗非班介入治疗;对照组予行冠状动脉内单纯导管血栓抽吸介入治疗。比较分析两组疗效。结果两组术后LVEF、LVEDE、LVESE、肌酸激酶(CK)及肌酸激酶同工酶(CK—MB)变化差异有统计学意义(P〈0.05)。结论冠状动脉内导管血栓抽吸术联合盐酸替罗非班介入治疗急性sT段抬高型心肌梗死效果显著。
出处 《中国实用医药》 2013年第35期160-161,共2页 China Practical Medicine
  • 相关文献

参考文献3

二级参考文献36

  • 1杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:73
  • 2Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprmein II h/IIIma inhibitors in acute coronary syndromes: a recta-analysis of all major randomised clinical trials[J].Lancet,2002,359(9302) : 189- 198.
  • 3Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST Elevation Myocardial Infarction: [J]. Circulation, 2008,117(2): 296- 329.
  • 4Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirnfiban with aspirin plus heparin for unstable angina [J]. NEnglJ Med,1998,338(21):1498-1505.
  • 5The PRISM PLUS Study Investigators: Inhibition of the platelet glycoprotein II b/III a receptor with tirofiban in unstable angi na and non-Q wave myocardial infarction [J].N Engl J Med, 1998,338(21) :1488- 1497.
  • 6The RESTORE Investigators: Effects of platelet glycoprotein II b/III a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation, 7997,96(5) : 1445-1453.
  • 7Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial[J]. JAMA, 2008,299(15) :1788 -1799.
  • 8Gian B, Cinzia C, Marco S,et al. , Variability in Extent of Platelet Function Inhibition After Administration of Optimal Dose of Glycoprotein II b/III a Receptor Blockers in Patients Undergoing a High Risk Percutaneous Coronary Intervention [J]. Am J CardioI, 2006, 97(4) : 489- 493.
  • 9Wayne B, Thaddeus R, Yao H, et al,Randomized COMparison of platelet inhibition with abciximab, WiRofiban and epti fibatide during percutaneous coronary intervention in acute coronary syndromes: The COMPARE Trial. [J].Circulation, 2002,106(12) : 1470-1476.
  • 10Topol EJ, Moliterno DJ,et al. Herrmann HC,Comparison of two platelet glycoprotein II b/III a inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutane ous coronary revascularization [J]. N Engl J Med , 2001, 344(25) : 1888-1894.

共引文献9

同被引文献16

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部